_256_384.jpg)
News | December 08, 2021
IPM registers 6 % yoy revenue growth in Nov 2021.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
Fujifilm India will be providing healthcare Imaging devices and equipment’s to increase the standards of the veterinary care in India.
It is an extension of GE Healthcare’s online service delivery enterprise Service Shop
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
Subscribe To Our Newsletter & Stay Updated
